BeiGene Plans $127 Million U.S. IPO In February
Published: Jan 21, 2016
BeiGene, an innovative biopharma located in Beijing, hopes to raise $126.5 million in its NASDAQ IPO, currently scheduled to take place in the first week of February. BeiGene is a cancer-focused company that develops molecularly targeted and immuno-oncology drugs. The IPO values six-year-old BeiGene at close to $900 million. The company, which has four drug candidates in Phase I trials, is facing a cautious market after several years of very positive biopharma IPO conditions. Two of BeiGene's venture backers indicated they might like to buy 50% of the offering.